Cargando…
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic di...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/ https://www.ncbi.nlm.nih.gov/pubmed/35632402 http://dx.doi.org/10.3390/vaccines10050646 |
_version_ | 1784715672293474304 |
---|---|
author | Gisondi, Paolo Geat, Davide Maurelli, Martina Degli Esposti, Luca Bellinato, Francesco Girolomoni, Giampiero |
author_facet | Gisondi, Paolo Geat, Davide Maurelli, Martina Degli Esposti, Luca Bellinato, Francesco Girolomoni, Giampiero |
author_sort | Gisondi, Paolo |
collection | PubMed |
description | Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab. |
format | Online Article Text |
id | pubmed-9142895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91428952022-05-29 Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease Gisondi, Paolo Geat, Davide Maurelli, Martina Degli Esposti, Luca Bellinato, Francesco Girolomoni, Giampiero Vaccines (Basel) Article Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab. MDPI 2022-04-20 /pmc/articles/PMC9142895/ /pubmed/35632402 http://dx.doi.org/10.3390/vaccines10050646 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gisondi, Paolo Geat, Davide Maurelli, Martina Degli Esposti, Luca Bellinato, Francesco Girolomoni, Giampiero Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title_full | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title_fullStr | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title_full_unstemmed | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title_short | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease |
title_sort | cost per responder analysis of secukinumab versus adalimumab in the treatment of psoriatic disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/ https://www.ncbi.nlm.nih.gov/pubmed/35632402 http://dx.doi.org/10.3390/vaccines10050646 |
work_keys_str_mv | AT gisondipaolo costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease AT geatdavide costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease AT maurellimartina costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease AT degliespostiluca costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease AT bellinatofrancesco costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease AT girolomonigiampiero costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease |